These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 4039764

  • 1. Differential effects of prolactin on rat dorsolateral prostate and R3327 prostatic tumor sublines.
    Johnson MP, Thompson SA, Lubaroff DM.
    J Urol; 1985 Jun; 133(6):1112-20. PubMed ID: 4039764
    [Abstract] [Full Text] [Related]

  • 2. Role of prolactin in modulating the effects of tamoxifen on growth of the Dunning R3327 rat prostate adenocarcinoma.
    Sylvester PW, Ip MM.
    Prostate; 1987 Jun; 10(1):57-67. PubMed ID: 3822918
    [Abstract] [Full Text] [Related]

  • 3. Effects of olfactory bulbectomy, melatonin, and/or pinealectomy on three sublines of the Dunning R3327 rat prostatic adenocarcinoma.
    Toma JG, Amerongen HM, Hennes SC, O'Brien MG, McBlain WA, Buzzell GR.
    J Pineal Res; 1987 Jun; 4(3):321-38. PubMed ID: 3625464
    [Abstract] [Full Text] [Related]

  • 4. Growth of Dunning transplantable prostate adenocarcinomas in rats fed diets with various fat contents.
    Clinton SK, Palmer SS, Spriggs CE, Visek WJ.
    J Nutr; 1988 Jul; 118(7):908-14. PubMed ID: 3392600
    [Abstract] [Full Text] [Related]

  • 5. Vascular endothelial growth factor content in metastasizing and nonmetastasizing Dunning prostatic adenocarcinoma.
    Häggström S, Bergh A, Damber JE.
    Prostate; 2000 Sep 15; 45(1):42-50. PubMed ID: 10960841
    [Abstract] [Full Text] [Related]

  • 6. Dietary fat and protein intake differ in modulation of prostate tumor growth, prolactin secretion and metabolism, and prostate gland prolactin binding capacity in rats.
    Clinton SK, Mulloy AL, Li SP, Mangian HJ, Visek WJ.
    J Nutr; 1997 Feb 15; 127(2):225-37. PubMed ID: 9039822
    [Abstract] [Full Text] [Related]

  • 7. Development of an in vitro clonogenic assay for the R3327 rat prostatic adenocarcinoma permits comparison of the proliferative potential of the R3327, R3327A, and R3327AT tumors.
    Dibner JJ, Nakeff A.
    Prostate; 1983 Feb 15; 4(3):289-306. PubMed ID: 6844160
    [Abstract] [Full Text] [Related]

  • 8. Action of prolactin in regressing prostate: independent of action mediated by androgen receptors.
    Assimos D, Smith C, Lee C, Grayhack JT.
    Prostate; 1984 Feb 15; 5(6):589-95. PubMed ID: 6494057
    [Abstract] [Full Text] [Related]

  • 9. Effect of active immunization against luteinizing hormone-releasing hormone on the androgen-sensitive Dunning R3327-PAP and androgen-independent Dunning R3327-AT2.1 prostate cancer sublines.
    Fuerst J, Fiebiger E, Jungwirth A, Mack D, Talwar PG, Frick J, Rovan E.
    Prostate; 1997 Jul 01; 32(2):77-84. PubMed ID: 9215394
    [Abstract] [Full Text] [Related]

  • 10. Differential sensitivity of three sublines of the rat Dunning prostate tumor system R3327 to radiation and/or local tumor hyperthermia.
    Peschke P, Hahn EW, Wenz F, Lohr F, Braunschweig F, Wolber G, Zuna I, Wannenmacher M.
    Radiat Res; 1998 Oct 01; 150(4):423-30. PubMed ID: 9768856
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Flow cytometric analysis of R3327 rat prostate adenocarcinoma grown in vivo and in vitro.
    Claflin AJ, Pollack A, Malinin T, Block NL, Irvin GL.
    J Natl Cancer Inst; 1982 Jul 01; 69(1):79-87. PubMed ID: 6954325
    [Abstract] [Full Text] [Related]

  • 14. The relationship of androgen receptor levels to androgen responsiveness in the Dunning R3327 rat prostate tumor sublines.
    Diamond DA, Barrack ER.
    J Urol; 1984 Oct 01; 132(4):821-7. PubMed ID: 6471235
    [Abstract] [Full Text] [Related]

  • 15. Flow cytometric characterization of tumor subpopulations in three sublines of the Dunning R3327 rat prostate tumor model.
    Glowa C, Peschke P, Karger CP, Hahn EW, Huber PE, Debus J, Ehemann V.
    Prostate; 2013 Nov 01; 73(15):1710-20. PubMed ID: 23853045
    [Abstract] [Full Text] [Related]

  • 16. Metabolic action of prolactin in regressing prostate: independent of androgen action.
    Smith C, Assimos D, Lee C, Grayhack JT.
    Prostate; 1985 Nov 01; 6(1):49-59. PubMed ID: 3969372
    [Abstract] [Full Text] [Related]

  • 17. Detection of mRNA expression of gonadotropin-releasing hormone and its receptor in normal and neoplastic rat prostates.
    Lau HL, Zhu XM, Leung PC, Chan LW, Chen GF, Chan PS, Yu KL, Chan FL.
    Int J Oncol; 2001 Dec 01; 19(6):1193-201. PubMed ID: 11713589
    [Abstract] [Full Text] [Related]

  • 18. Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo.
    Garde S, Sheth A, Porter AT, Pienta KJ.
    Prostate; 1993 Dec 01; 22(3):225-33. PubMed ID: 8488155
    [Abstract] [Full Text] [Related]

  • 19. Acid phosphatase-producing androgen-independent subline of rat prostatic adenocarcinoma (Dunning R3327 tumor) in cell culture.
    Igarashi T, Isaka S, Miyauchi T, Hayata I, Shimazaki J.
    Prostate; 1984 Dec 01; 5(1):113-22. PubMed ID: 6694915
    [Abstract] [Full Text] [Related]

  • 20. Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma.
    Zaccheo T, Giudici D, di Salle E.
    Prostate; 1997 Feb 01; 30(2):85-91. PubMed ID: 9051146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.